{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T11:19:42Z","timestamp":1788520782180,"version":"build-2803163510"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T00:00:00Z","timestamp":1754524800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T00:00:00Z","timestamp":1754524800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1038\/s41591-025-03802-8","type":"journal-article","created":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T09:03:04Z","timestamp":1754557384000},"page":"3062-3073","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Adjuvant nivolumab in muscle-invasive urothelial carcinoma: exploratory biomarker analysis of the randomized phase 3 CheckMate 274 trial"],"prefix":"10.1038","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7655-9378","authenticated-orcid":false,"given":"Matthew D.","family":"Galsky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4001-7088","authenticated-orcid":false,"given":"Dean F.","family":"Bajorin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7465-9591","authenticated-orcid":false,"given":"Yoshihiko","family":"Tomita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4974-3780","authenticated-orcid":false,"given":"Dingwei","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3923-6136","authenticated-orcid":false,"given":"Mads","family":"Agerbaek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Enting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avivit","family":"Peer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8965-8129","authenticated-orcid":false,"given":"Matthew","family":"Milowsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ko","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc-Oliver","family":"Grimm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Stenner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2151-605X","authenticated-orcid":false,"given":"Justin M.","family":"David","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott D.","family":"Chasalow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Nasroulah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abraham","family":"Apfel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keziban","family":"\u00dcnsal-Ka\u00e7maz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3007-2756","authenticated-orcid":false,"given":"Andrea","family":"Necchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,7]]},"reference":[{"key":"3802_CR1","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","volume":"384","author":"DF Bajorin","year":"2021","unstructured":"Bajorin, D. F. et al. Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma. N. Engl. J. Med. 384, 2102\u20132114 (2021).","journal-title":"N. Engl. J. Med."},{"key":"3802_CR2","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1200\/JCO.24.00340","volume":"43","author":"MD Galsky","year":"2025","unstructured":"Galsky, M.D. et al. Adjuvant nivolumab in high-risk muscle-invasive urothelial carcinoma: expanded efficacy from CheckMate 274. J Clin Oncol. 43, 15\u201321 (2025).","journal-title":"J Clin Oncol."},{"key":"3802_CR3","unstructured":"Ono Pharmaceutical Ltd. Ono receives supplemental approval of Opdivo\u00ae (nivolumab) for adjuvant treatment of urothelial carcinoma in Japan. Ono Pharma https:\/\/www.ono-pharma.com\/en\/news\/20220328.html (2022)."},{"key":"3802_CR4","unstructured":"Opdivo (nivolumab), package insert (Bristol Myers Squibb, 2023)."},{"key":"3802_CR5","unstructured":"Opidivo (nivolumab), summary of product characteristics (Bristol Myers Squibb, 2023)."},{"key":"3802_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-05992-x","volume":"9","author":"L Wang","year":"2018","unstructured":"Wang, L. et al. EMT- and stroma-related gene expression and resistance to PD-1 blockade in urothelial cancer. Nat. Commun. 9, 3503 (2018).","journal-title":"Nat. Commun."},{"key":"3802_CR7","doi-asserted-by":"crossref","first-page":"4287","DOI":"10.1158\/1078-0432.CCR-20-4574","volume":"27","author":"L Wang","year":"2021","unstructured":"Wang, L. et al. Myeloid cell-associated resistance to PD-1\/PD-L1 blockade in urothelial cancer revealed through bulk and single-cell RNA sequencing. Clin. Cancer Res. 27, 4287\u20134300 (2021).","journal-title":"Clin. Cancer Res."},{"key":"3802_CR8","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/nature25501","volume":"554","author":"S Mariathasan","year":"2018","unstructured":"Mariathasan, S. et al. TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature 554, 544\u2013548 (2018).","journal-title":"Nature"},{"key":"3802_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-24112-w","volume":"12","author":"R Banchereau","year":"2021","unstructured":"Banchereau, R. et al. Molecular determinants of response to PD-L1 blockade across tumor types. Nat. Commun. 12, 3969 (2021).","journal-title":"Nat. Commun."},{"key":"3802_CR10","doi-asserted-by":"crossref","first-page":"eabc4220","DOI":"10.1126\/scitranslmed.abc4220","volume":"12","author":"S Goswami","year":"2020","unstructured":"Goswami, S. et al. ARID1A mutation plus CXCL13 expression act as combinatorial biomarkers to predict responses to immune checkpoint therapy in mUCC. Sci. Transl. Med. 12, eabc4220 (2020).","journal-title":"Sci. Transl. Med."},{"key":"3802_CR11","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1038\/s41591-021-01579-0","volume":"27","author":"T Powles","year":"2021","unstructured":"Powles, T. et al. Avelumab maintenance in advanced urothelial carcinoma: biomarker analysis of the phase 3 JAVELIN Bladder 100 trial. Nat. Med. 27, 2200\u20132211 (2021).","journal-title":"Nat. Med."},{"key":"3802_CR12","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/S1470-2045(17)30065-7","volume":"18","author":"P Sharma","year":"2017","unstructured":"Sharma, P. et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 18, 312\u2013322 (2017).","journal-title":"Lancet Oncol."},{"key":"3802_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-06654-8","volume":"9","author":"A Chakravarthy","year":"2018","unstructured":"Chakravarthy, A., Khan, L., Bensler, N. P., Bose, P. & De Carvalho, D. D. TGF-\u03b2-associated extracellular matrix genes link cancer-associated fibroblasts to immune evasion and immunotherapy failure. Nat. Commun. 9, 4692 (2018).","journal-title":"Nat. Commun."},{"key":"3802_CR14","doi-asserted-by":"crossref","first-page":"5120","DOI":"10.1158\/1078-0432.CCR-19-4162","volume":"26","author":"MD Galsky","year":"2020","unstructured":"Galsky, M. D. et al. Nivolumab in patients with advanced platinum-resistant urothelial carcinoma: efficacy, safety, and biomarker analyses with extended follow-up from CheckMate 275. Clin. Cancer Res. 26, 5120\u20135128 (2020).","journal-title":"Clin. Cancer Res."},{"key":"3802_CR15","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1200\/JCO.2023.41.16_suppl.2503","volume":"41","author":"DR Gandara","year":"2023","unstructured":"Gandara, D. R. et al. Tumor mutational burden (TMB) measurement from an FDA-approved assay and real-world overall survival (rwOS) on single-agent immune checkpoint inhibitors (ICI) in over 8,000 patients across 24 cancer types. J. Clin. Oncol. 41, 2503 (2023).","journal-title":"J. Clin. Oncol."},{"key":"3802_CR16","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1200\/JCO.2022.40.6_suppl.540","volume":"40","author":"R Morales-Barrera","year":"2022","unstructured":"Morales-Barrera, R. et al. Association of TMB and PD-L1 with efficacy of first-line pembrolizumab (pembro) or pembro + chemotherapy (chemo) versus chemo in patients (pts) with advanced urothelial carcinoma (UC) from KEYNOTE-361. J. Clin. Oncol. 40, 540 (2022).","journal-title":"J. Clin. Oncol."},{"key":"3802_CR17","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/s41571-021-00473-5","volume":"18","author":"DB Doroshow","year":"2021","unstructured":"Doroshow, D. B. et al. PD-L1 as a biomarker of response to immune-checkpoint inhibitors. Nat. Rev. Clin. Oncol. 18, 345\u2013362 (2021).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"3802_CR18","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.eururo.2023.01.016","volume":"83","author":"MD Galsky","year":"2023","unstructured":"Galsky, M. D. et al. Disease-free survival analysis for patients with high-risk muscle-invasive urothelial carcinoma from the randomized CheckMate 274 trial by PD-L1 combined positive score and tumor cell score. Eur. Urol. 83, 432\u2013440 (2023).","journal-title":"Eur. Urol."},{"key":"3802_CR19","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1038\/s41591-020-1086-y","volume":"26","author":"J Gao","year":"2020","unstructured":"Gao, J. et al. Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma. Nat. Med. 26, 1845\u20131851 (2020).","journal-title":"Nat. Med."},{"key":"3802_CR20","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.eururo.2019.09.006","volume":"77","author":"A Kamoun","year":"2020","unstructured":"Kamoun, A. et al. A consensus molecular classification of muscle-invasive bladder cancer. Eur. Urol. 77, 420\u2013433 (2020).","journal-title":"Eur. Urol."},{"key":"3802_CR21","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","volume":"171","author":"AG Robertson","year":"2017","unstructured":"Robertson, A. G. et al. Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell 171, 540\u2013556 e525 (2017).","journal-title":"Cell"},{"key":"3802_CR22","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1016\/j.cell.2019.02.012","volume":"176","author":"M Petljak","year":"2019","unstructured":"Petljak, M. et al. Characterizing mutational signatures in human cancer cell lines reveals episodic APOBEC mutagenesis. Cell 176, 1282\u20131294 e1220 (2019).","journal-title":"Cell"},{"key":"3802_CR23","volume":"8","author":"A Prosz","year":"2024","unstructured":"Prosz, A. et al. Mutational signature-based identification of DNA repair deficient gastroesophageal adenocarcinomas for therapeutic targeting. NPJ Precis. Oncol. 8, 87 (2024).","journal-title":"NPJ Precis. Oncol."},{"key":"3802_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-10987-3","volume":"10","author":"J Sun","year":"2019","unstructured":"Sun, J. et al. Genomic signatures reveal DNA damage response deficiency in colorectal cancer brain metastases. Nat. Commun. 10, 3190 (2019).","journal-title":"Nat. Commun."},{"key":"3802_CR25","doi-asserted-by":"crossref","first-page":"4181","DOI":"10.7150\/thno.73235","volume":"12","author":"R Shi","year":"2022","unstructured":"Shi, R. et al. APOBEC-mediated mutagenesis is a favorable predictor of prognosis and immunotherapy for bladder cancer patients: evidence from pan-cancer analysis and multiple databases. Theranostics 12, 4181\u20134199 (2022).","journal-title":"Theranostics"},{"key":"3802_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-25894-9","volume":"12","author":"G Han","year":"2021","unstructured":"Han, G. et al. 9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy. Nat. Commun. 12, 5606 (2021).","journal-title":"Nat. Commun."},{"key":"3802_CR27","doi-asserted-by":"crossref","first-page":"eaar3593","DOI":"10.1126\/science.aar3593","volume":"362","author":"R Cristescu","year":"2018","unstructured":"Cristescu, R. et al. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. Science 362, eaar3593 (2018).","journal-title":"Science"},{"key":"3802_CR28","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s11222-013-9424-2","volume":"25","author":"P Breheny","year":"2015","unstructured":"Breheny, P. & Huang, J. Group descent algorithms for nonconvex penalized linear and logistic regression models with grouped predictors. Stat. Comput. 25, 173\u2013187 (2015).","journal-title":"Stat. Comput."},{"key":"3802_CR29","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.eururo.2019.05.037","volume":"76","author":"SA Niglio","year":"2019","unstructured":"Niglio, S. A. et al. Programmed death-1 or programmed death ligand-1 blockade in patients with platinum-resistant metastatic urothelial cancer: a systematic review and meta-analysis. Eur. Urol. 76, 782\u2013789 (2019).","journal-title":"Eur. Urol."},{"key":"3802_CR30","first-page":"608","volume":"10","author":"T-B Huang","year":"2017","unstructured":"Huang, T.-B. et al. A novel 13-gene signature of TGF-beta pathway correlates with tumor stage and grade and predicts poor survival for bladder cancer patients. Int. J. Clin. Exp. Med. 10, 608\u2013617 (2017).","journal-title":"Int. J. Clin. Exp. Med."},{"key":"3802_CR31","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1016\/j.cell.2020.05.017","volume":"181","author":"DY Oh","year":"2020","unstructured":"Oh, D. Y. et al. Intratumoral CD4+ T cells mediate anti-tumor cytotoxicity in human bladder cancer. Cell 181, 1612\u20131625 e1613 (2020).","journal-title":"Cell"},{"key":"3802_CR32","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1172\/JCI91190","volume":"127","author":"M Ayers","year":"2017","unstructured":"Ayers, M. et al. IFN-\u03b3-related mRNA profile predicts clinical response to PD-1 blockade. J. Clin. Invest. 127, 2930\u20132940 (2017).","journal-title":"J. Clin. Invest."},{"key":"3802_CR33","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1038\/s43018-022-00338-5","volume":"3","author":"M Cohen","year":"2022","unstructured":"Cohen, M. et al. The interaction of CD4+ helper T cells with dendritic cells shapes the tumor microenvironment and immune checkpoint blockade response. Nat. Cancer 3, 303\u2013317 (2022).","journal-title":"Nat. Cancer"},{"key":"3802_CR34","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1038\/s41591-023-02345-0","volume":"29","author":"A Magen","year":"2023","unstructured":"Magen, A. et al. Intratumoral dendritic cell-CD4+ T helper cell niches enable CD8+ T cell differentiation following PD-1 blockade in hepatocellular carcinoma. Nat. Med. 29, 1389\u20131399 (2023).","journal-title":"Nat. Med."},{"key":"3802_CR35","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1158\/2159-8290.CD-22-0201","volume":"12","author":"AG Goubet","year":"2022","unstructured":"Goubet, A. G. et al. Escherichia coli-specific CXCL13-producing TFH are associated with clinical efficacy of neoadjuvant PD-1 blockade against muscle-invasive bladder cancer. Cancer Discov. 12, 2280\u20132307 (2022).","journal-title":"Cancer Discov."},{"key":"3802_CR36","doi-asserted-by":"crossref","first-page":"4685","DOI":"10.1158\/1078-0432.CCR-21-0327","volume":"27","author":"L Marcus","year":"2021","unstructured":"Marcus, L. et al. FDA approval summary: pembrolizumab for the treatment of tumor mutational burden-high solid tumors. Clin. Cancer Res. 27, 4685\u20134689 (2021).","journal-title":"Clin. Cancer Res."},{"key":"3802_CR37","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/j.ccell.2022.08.022","volume":"40","author":"AH Nassar","year":"2022","unstructured":"Nassar, A. H. et al. Ancestry-driven recalibration of tumor mutational burden and disparate clinical outcomes in response to immune checkpoint inhibitors. Cancer Cell 40, 1161\u20131172 e1165 (2022).","journal-title":"Cancer Cell"},{"key":"3802_CR38","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1001\/jamaoncol.2020.7684","volume":"7","author":"C Valero","year":"2021","unstructured":"Valero, C. et al. Response rates to anti-PD-1 immunotherapy in microsatellite-stable solid tumors with 10 or more mutations per megabase. JAMA Oncol. 7, 739\u2013743 (2021).","journal-title":"JAMA Oncol."},{"key":"3802_CR39","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1093\/annonc\/mdx410","volume":"28","author":"MR Spears","year":"2017","unstructured":"Spears, M. R., James, N. D. & Sydes, M. R. \u201cThursday\u2019s child has far to go\u201d-interpreting subgroups and the STAMPEDE trial. Ann. Oncol. 28, 2327\u20132330 (2017).","journal-title":"Ann. Oncol."},{"key":"3802_CR40","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.eururo.2022.04.013","volume":"82","author":"B Szabados","year":"2022","unstructured":"Szabados, B. et al. Final results of neoadjuvant atezolizumab in cisplatin-ineligible patients with muscle-invasive urothelial cancer of the bladder. Eur. Urol. 82, 212\u2013222 (2022).","journal-title":"Eur. Urol."},{"key":"3802_CR41","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1038\/s41586-021-03642-9","volume":"595","author":"T Powles","year":"2021","unstructured":"Powles, T. et al. ctDNA guiding adjuvant immunotherapy in urothelial carcinoma. Nature 595, 432\u2013437 (2021).","journal-title":"Nature"},{"key":"3802_CR42","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1097\/PAI.0000000000000256","volume":"23","author":"T Phillips","year":"2015","unstructured":"Phillips, T. et al. Development of an automated PD-L1 immunohistochemistry (IHC) assay for non-small cell lung cancer. Appl. Immunohistochem. Mol. Morphol. 23, 541\u2013549 (2015).","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"key":"3802_CR43","doi-asserted-by":"crossref","first-page":"e004316","DOI":"10.1136\/jitc-2021-004316","volume":"10","author":"RJ Motzer","year":"2022","unstructured":"Motzer, R. J. et al. Biomarker analysis from CheckMate 214: nivolumab plus ipilimumab versus sunitinib in renal cell carcinoma. J. Immunother. Cancer 10, e004316 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"3802_CR44","first-page":"A1330","volume":"10","author":"M Guramare","year":"2022","unstructured":"Guramare, M. et al. 1282 Concordance analysis of AI-powered CD8 quantification and automated CD8 topology with manual histopathological assessment across seven solid tumor types. J. Immunother. Cancer 10, A1330 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"3802_CR45","first-page":"A420","volume":"9","author":"G Lee","year":"2021","unstructured":"Lee, G. et al. 387 The utility of AI-powered spatial classification of intratumoral CD8+ immune-cell distribution in predicting overall survival in patients with melanoma as part of the CheckMate 067 clinical trial. J. Immunother. Cancer 9, A420 (2021).","journal-title":"J. Immunother. Cancer"},{"key":"3802_CR46","doi-asserted-by":"publisher","unstructured":"Weber, J., Aldana, R., Gallagher, B. & Edwards, J. Sentieon DNA pipeline for variant detection \u2013 software-only solution, over 20\u00d7 faster than GATK 3.3 with identical results. Preprint at https:\/\/doi.org\/10.7287\/peerj.preprints.1672v1 (2016).","DOI":"10.7287\/peerj.preprints.1672v1"},{"key":"3802_CR47","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1101\/gr.107524.110","volume":"20","author":"A McKenna","year":"2010","unstructured":"McKenna, A. et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 20, 1297\u20131303 (2010).","journal-title":"Genome Res."},{"key":"3802_CR48","unstructured":"Li, H. Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM. Preprint at https:\/\/arxiv.org\/abs\/1303.3997 (2013)."},{"key":"3802_CR49","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1093\/bioinformatics\/btp698","volume":"26","author":"H Li","year":"2010","unstructured":"Li, H. & Durbin, R. Fast and accurate long-read alignment with Burrows\u2013Wheeler transform. Bioinformatics 26, 589\u2013595 (2010).","journal-title":"Bioinformatics"},{"key":"3802_CR50","doi-asserted-by":"crossref","first-page":"i318","DOI":"10.1093\/bioinformatics\/bts414","volume":"28","author":"Y Liu","year":"2012","unstructured":"Liu, Y. & Schmidt, B. Long read alignment based on maximal exact match seeds. Bioinformatics 28, i318\u2013i324 (2012).","journal-title":"Bioinformatics"},{"key":"3802_CR51","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.ccell.2018.04.001","volume":"33","author":"MD Hellmann","year":"2018","unstructured":"Hellmann, M. D. et al. Tumor mutational burden and efficacy of nivolumab monotherapy and in combination with ipilimumab in small-cell lung cancer. Cancer Cell 33, 853\u2013861. e854 (2018).","journal-title":"Cancer Cell"},{"key":"3802_CR52","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1093\/nar\/29.1.308","volume":"29","author":"ST Sherry","year":"2001","unstructured":"Sherry, S. T. et al. dbSNP: the NCBI database of genetic variation. Nucleic Acids Res. 29, 308\u2013311 (2001).","journal-title":"Nucleic Acids Res."},{"key":"3802_CR53","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/nbt.2514","volume":"31","author":"K Cibulskis","year":"2013","unstructured":"Cibulskis, K. et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat. Biotechnol. 31, 213\u2013219 (2013).","journal-title":"Nat. Biotechnol."},{"key":"3802_CR54","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/s41592-018-0051-x","volume":"15","author":"S Kim","year":"2018","unstructured":"Kim, S. et al. Strelka2: fast and accurate calling of germline and somatic variants. Nat. Methods 15, 591\u2013594 (2018).","journal-title":"Nat. Methods"},{"key":"3802_CR55","doi-asserted-by":"crossref","first-page":"80","DOI":"10.4161\/fly.19695","volume":"6","author":"P Cingolani","year":"2012","unstructured":"Cingolani, P. et al. A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3. Fly (Austin) 6, 80\u201392 (2012).","journal-title":"Fly (Austin)"},{"key":"3802_CR56","doi-asserted-by":"crossref","first-page":"D777","DOI":"10.1093\/nar\/gkw1121","volume":"45","author":"SA Forbes","year":"2017","unstructured":"Forbes, S. A. et al. COSMIC: somatic cancer genetics at high-resolution. Nucleic Acids Res. 45, D777\u2013D783 (2017).","journal-title":"Nucleic Acids Res."},{"key":"3802_CR57","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1038\/s41586-020-2308-7","volume":"581","author":"KJ Karczewski","year":"2020","unstructured":"Karczewski, K. J. et al. The mutational constraint spectrum quantified from variation in 141,456 humans. Nature 581, 434\u2013443 (2020).","journal-title":"Nature"},{"key":"3802_CR58","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/nature15393","volume":"526","author":"The 1000 Genomes Project Consortium.","year":"2015","unstructured":"The 1000 Genomes Project Consortium. A global reference for human genetic variation. Nature 526, 68\u201374 (2015).","journal-title":"Nature"},{"key":"3802_CR59","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1038\/nbt.1975","volume":"29","author":"MJ Clark","year":"2011","unstructured":"Clark, M. J. et al. Performance comparison of exome DNA sequencing technologies. Nat. Biotechnol. 29, 908\u2013914 (2011).","journal-title":"Nat. Biotechnol."},{"key":"3802_CR60","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1007\/s40291-019-00408-y","volume":"23","author":"H Chang","year":"2019","unstructured":"Chang, H. et al. Bioinformatic methods and bridging of assay results for reliable tumor mutational burden assessment in non-small-cell lung cancer. Mol. Diagn. Ther. 23, 507\u2013520 (2019).","journal-title":"Mol. Diagn. Ther."},{"key":"3802_CR61","doi-asserted-by":"publisher","DOI":"10.1186\/s12864-019-6041-2","volume":"20","author":"EN Bergstrom","year":"2019","unstructured":"Bergstrom, E. N. et al. SigProfilerMatrixGenerator: a tool for visualizing and exploring patterns of small mutational events. BMC Genomics 20, 685 (2019).","journal-title":"BMC Genomics"},{"key":"3802_CR62","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-016-0893-4","volume":"17","author":"R Rosenthal","year":"2016","unstructured":"Rosenthal, R., McGranahan, N., Herrero, J., Taylor, B. S. & Swanton, C. DeconstructSigs: delineating mutational processes in single tumors distinguishes DNA repair deficiencies and patterns of carcinoma evolution. Genome Biol. 17, 31 (2016).","journal-title":"Genome Biol."},{"key":"3802_CR63","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1002\/sim.3107","volume":"27","author":"A Gelman","year":"2008","unstructured":"Gelman, A. Scaling regression inputs by dividing by two standard deviations. Stat. Med. 27, 2865\u20132873 (2008).","journal-title":"Stat. Med."},{"key":"3802_CR64","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1002\/sim.8505","volume":"39","author":"M Zhang","year":"2020","unstructured":"Zhang, M. et al. Interaction analysis under misspecification of main effects: some common mistakes and simple solutions. Stat. Med. 39, 1675\u20131694 (2020).","journal-title":"Stat. Med."},{"key":"3802_CR65","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1080\/01621459.2014.951443","volume":"109","author":"L Tian","year":"2014","unstructured":"Tian, L., Alizadeh, A. A., Gentles, A. J. & Tibshirani, R. A simple method for estimating interactions between a treatment and a large number of covariates. J. Am. Stat. Assoc. 109, 1517\u20131532 (2014).","journal-title":"J. Am. Stat. Assoc."},{"key":"3802_CR66","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4","volume":"15","author":"FE Harrell Jr","year":"1996","unstructured":"Harrell, F. E. Jr, Lee, K. L. & Mark, D. B. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat. Med. 15, 361\u2013387 (1996).","journal-title":"Stat. Med."},{"key":"3802_CR67","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/j.0006-341X.2000.00337.x","volume":"56","author":"PJ Heagerty","year":"2000","unstructured":"Heagerty, P. J., Lumley, T. & Pepe, M. S. Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics 56, 337\u2013344 (2000).","journal-title":"Biometrics"}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03802-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03802-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03802-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T11:04:03Z","timestamp":1788519843000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03802-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,7]]},"references-count":67,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["3802"],"URL":"https:\/\/doi.org\/10.1038\/s41591-025-03802-8","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,7]]},"assertion":[{"value":"28 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.D.G. reports consulting roles with BioMotiv, Janssen, Dendreon, Merck, GlaxoSmithKline, Lilly, Astellas Pharma, Genentech, Bristol Myers Squibb (BMS), Novartis, Pfizer, EMD Serono, AstraZeneca, Seattle Genetics, Incyte, Aileron Therapeutics, Dracen, Inovio Pharmaceuticals, NuMab, Dragonfly Therapeutics, Basilea, UroGen Pharma, Infinity Pharmaceuticals, Gilead Sciences and Silverback Therapeutics; stock ownership with Rappta Therapeutics; and research funding with Janssen Oncology, Dendreon, Novartis, BMS, Merck, AstraZeneca and Genentech\/Roche. D.F.B. reports consulting roles with Merck, Dragonfly Therapeutics, Fidia Farmaceutici S.p.A. and BMS Foundation; travel with Merck; and research funding to their institution with Novartis, Merck, BMS, AstraZeneca, Astellas Pharma and Seattle Genetics\/Astellas. Y.T. reports consulting roles with Eisai, MSD and Ono Pharmaceutical; honoraria with Astellas Pharma, BMS Japan, Chugai Pharma, Novartis and Ono Pharmaceutical; and research funding to their institution with Astellas Pharma, AstraZeneca, Chugai Pharma, Eisai, MSD, Novartis, Ono Pharmaceutical, Pfizer and Takeda. D.Y. declares no conflicts of interest. M.A. declares no conflicts of interest. D.E. reports institution financial interests with Astellas for Bladder Cancer Preceptorship, Bayer for Ra223 advisory board and Janssen for Prostate Cancer UK Summit. A.P. reports being on advisory boards with Astellas, Bayer, BMS, Exelixis, Janssen, Medison Pharma, MSD, Takada and Teva; expert testimony with Roche; and an Institutional research grant from Sanofi (no financial interest). M.M. reports being an advisory board or invited speaker with Elsevier, Loxo\/Lilly and Medscape; a co-editor-in-chief with Elsevier; having stocks and shares with Gilead Sciences, Merck and Pfizer; and institutional financial interests from Accuray, Acrivon Therapeutics, Alliance for Clinical Trials in Oncology, Alliance Foundation Trials, ALX Oncology, Amgen, Arvinas, Astellas Pharma, AstraZeneca\/MedImmune, Bayer, BMS, Boehringer Ingelheim, Clovis Oncology, Constellation Pharmaceuticals, G1 Therapeutics, Hoosier Cancer Research Network, Incyte, Loxo, Merck, Mirati Therapeutics, Novartis, Prostate Cancer Clinical Trials Consortium, Roche\/Genentech and Seagen. K.K. declares no conflicts of interest. M.O.-G. reports honoraria with AstraZeneca, MSD, Pfizer, Ipsen, Merck Serono, EUSA Pharma and Janssen Cilag; consulting roles with AstraZeneca, BMS, Ipsen, MSD, Pfizer, EUSA Pharma, Merck Serono, Takeda, Eisai, Bayer Vital and Janssen Cilag; research funding to their institution with BMS, Intuitive Surgical and Bayer Vital; and travel with BMS, Merck Serono, MSD, Janssen Cilag, Ipsen and AstraZeneca. F.S. reports institutional financial interests with BMS, Ipsen, MSD, Pfizer and Roche for advisory boards; institutional financial interests with BMS for being coordinating principal investigator; and no personal financial interests. J.M.D., J.L., S.D.C., F.N., A.A. and K.\u00dc.-K. report previous employment with and ownership of stock in BMS. A.N. reports consulting roles with Roche, Janssen, Bayer, Astellas, AstraZeneca, Merck, Clovis Oncology, Incyte and Pfizer; research grant to their institution from Merck, AstraZeneca, Ipsen, BMS and Gilead; and a nonfinancial leadership role with the Global Society of Rare Genitourinary Tumors.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}